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Background: Limited experience with bioprosthetic venous valve percutaneously inserted into femoral veins in 15 patients
has been promising in short-term results only to show disappointing long-term results. Percutaneous autogenous venous
valve (PAVV) transplantation was explored in an ovine model as a possible alternative treatment.
Methods: PAVV consisted of a vein segment containing a valve that was attached to a stent template. The stent templates
(n  9) were designed and hand made in our research laboratory. They consist of two stainless steel square stents 13 or
15 mm in diameter to fit the ovine jugular veins (JV), which ranges from 10 to 15 mm in diameter. A valve-containing
segment of JV was harvested and attached with sutures and barbs inside the stent template (n 9). The valve devices were
then manually folded and front loaded inside the 4 cm chamber of the 13F delivery sheath and delivered into the
contralateral JV by femoral vein approach. Transplanted PAVVs were studied by immediate and 3 months venograms.
Animals were euthanized at 3 months, and jugular veins harvested to perform angioscopic evaluations in vitro.
Results: PAVV transplantation was successful in all nine animals. Good valve function with no reflux was observed on
immediate and 3 months venograms in eight valves. The transplanted maximal JV diameter ranged from 10.2 mm to 15.4
mm (mean 13.1  1.5 mm). Venoscopic examination revealed intact, flexible, nonthickened valve leaflets in eight
specimens. One PAVV exhibited normal function of one leaflet only; the other cusp was accidentally cut during the
transplantation procedure. All transplanted autologous valves were free of thrombus and incorporated into the vein wall
of the host vessel.
Conclusion: This study demonstrated that autogenous valve transplants remained patent and competent without
long-term anticoagulation for up to 3 months. The percutaneous autogenous venous valve may provide in future
minimally invasive treatment for patients with chronic deep venous insufficiency, but long-term studies need to be done
to document its continued patency and function. (J Vasc Surg 2007;46:338-45.)
Clinical Relevance: This report shows that leaflets lined with preserved endothelial cells prevented both neointima and
intimal hyperplasia and enhanced and prolong the functionality of the autologous valves. A critical issue in using
percutaneous autologous venous valve transplantation therapy and preventing thrombosis is the delivery of the
transplanted valve leaflet with its endothelial cells still intact and fully functioning.Chronic deep venous insufficiency (CDVI) remains a
major health problem in the United States and world-
wide.1,2 Selected patients have benefited from direct deep
vein valve surgical repair,3-8 femoral vein transposition, and
venous segment transplantation.9-11 A major limitation of
this approach is that most patients with postthrombotic
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338syndrome are not candidates for these procedures due to
obstructions or residual thrombus throughout the vein and
adverse anatomical conditions. In such cases, several ap-
proaches have been attempted with mixed results includ-
ing venous reflux correction with a cryopreserved vein
valve12,13 and an autologous valve reconstruction tech-
nique.14 Another approach involves inverting a saphenous
vein segment15,16 or constructing a neovalve using a neo-
intima of the vein wall.17 Limited experience with the
bioprosthetic venous valve18-20 percutaneously inserted
into the femoral vein in 15 patients has been promising in
short-term results only to show disappointing long-term
results.21We explored the feasibility of percutaneous autol-
ogous venous valve (PAVV) transplantation as a possible
alternative treatment in an ovine jugular vein (JV) model.
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Nine PAVVs were transplanted into the JVs of nine
adult female sheep weighing 51.7 to 66.2 kg (mean 58.5).
General inhalation anesthesia was employed during the
procedures as previously described.18-20 A GE-OEC 9800
cardiac mobile system with digital imaging (GE Medical
Systems, OEC, Salt Lake City, Utah) was used for imaging.
The institutional Animal Care and Use Committee of
the Oregon Health Science and University approved this
study.
Stent valve template (SVT). The PAVV consisted of a
short JV segment with a bicuspid valve (BV) that was attached
to the inside of a stent valve template (SVT). The self-
expanding SVT (n 9) handmade in our research laboratory
was constructed of a larger and a smaller square stent,22,23
joined togetherwith four shortmetal cannulas that also served
as radiopaquemarkers. The larger square stent of the SVThad
a short barb at each upper bend to provide anchors for the
valve during transplantation placement. To facilitate valve
attachment and placement an additional smaller square stent
with barb at each lower bend was attached to the midpoint of
the larger stent. The stainless steel SVTs with four barbs were
made from 0.010-inch wire in diameters of 13 and 15 mm to
fit the ovine JVs (Fig 1).
Animal experiment. Using sterile technique, a 6F
vascular sheath (Cook Medical, Bloomington, Ind) was
percutaneously introduced into each JV and a 6F H1
catheter (Cook Medical) into the right femoral vein. After
Fig 1. Stent valve template (SVT) 15 mm in diameter with four
barbs and four markers (arrows).administration of 100 IU/kg of heparin, the animals werepositioned into a head down position approximately 30
degrees for better filling of the veins during jugular
venograms. The diameter of each JV was measured using a
0.035-inch graduate measuring guide wire (CookMedical)
intraluminally placed for calibration. The ascending jugular
venograms were performed first to identify the number and
type of the valves. After the BV was selected for harvesting,
the H1 catheter was placed caudal to the selected valve for
the descending venography to document its function. Lo-
cation of the selected BV was marked with a needle on the
skin. A 260 cm long extra-stiff wire guide (Cook Medical)
was then introduced into the contralateral JV using the H1
curved catheter for later PAVV implantation.
Under sterile conditions, the marked JV segment was
surgically exposed. The selected BV with about a 4 cm long
segment of JV was harvested and immediately filled with
chilled Wisconsin University solution Via-Span (Belzer
UW-CSS, Dupont Pharmaceuticals, Wilmington, Del) to
decrease endothelial cell damage.24 After harvesting, the
excision site was then closed. Both ends of the harvested JV
segment were ligated with silk suture. The segment was
then distended with chilled Wisconsin University solution
and placed inside the STV. The ligated ends of the segment
were immobilized on a sterile wooden board using silk
suture and pins. The white semi-lunar lines formed by BV
commissures were seen in the distended vein segment wall
and helped to identify valve orientation (Fig 2, a). BV was
attached to the inside of a SVT. The apex of each commis-
sure was sutured to the tip of the smaller square stent bend
using 7.0 Prolene (Ethicon, Somerville, NJ) (Fig 2, b). The
opposite end of the BV vein inflow wall was then attached
with sutures and barbs inside the SVT to the inflow part.
After trimming the caudal transplant end of excessive vein,
the lateral valve sinus wall was partially cut longitudinally
and wrapped and sutured around each middle shorter
square stent bend. The valve opening was suspended be-
tween both shorter square stent bend. (Fig 2, c).
The completed PAVVwas placed over dilator with a cut
out for the PAVV then manually folded and front loaded
inside a 4 cm long chamber of the 13F delivery sheath
(Cook Inc, Bloomington, Ind). The sheath was flushed
with heparinized saline and then exchanged over previously
inserted a 260 cm long extra-stiff wire guide with the 6F
sheath in femoral vein. The PAVV was delivered into the
remaining JV across a native host valve by femoral ap-
proach. In each case, extrusion of the PAVV was accom-
plished by withdrawing the sheath, while holding the dila-
tor. During delivery the PAVV with barbs self-attached to
the vein wall. The dilator and guide wire were then re-
moved and the sheath left in the superior vena cava for
follow-up venograms with a 6F H1 side hole catheter.
PAVVs were anatomically oriented in the same direc-
tion as the natural valves of the host JV. Four markers of the
STV facilitated the correct circumferential anatomical spa-
tial orientation during deployment of the PAVV. Function
of the PAVV was studied immediately with contrast me-
dium injections cephalad and caudal to the transplanted
valve. The primary end point of the study was PAVV
demo
JOURNAL OF VASCULAR SURGERY
August 2007340 Pavcnik et alflexibility and pliability of the leaflets, with valve compe-
tence outcome as a secondary end point at 3 months.
Follow-up. Three months after the PAVVs transplan-
tation, the animals returned for follow-up descending and
ascending venograms using the previously described tech-
niques, then euthanized. The jugular veins were exposed
for gross examination and resected for the angioscopic
evaluation. This was performed in-vitro in a flow model
mounted in a vertical position. The caudal end of the vein
specimen was attached to a tube and water reservoir and
Fig 2. Autologous venous valve attached to a stent val
(arrow). White arrow demonstrates direction of the blood
template. The apex of each commissure is sutured to the t
venous valve attached to a stent valve template. Arrowsdistended with a pressure of 25 mm Hg. This pressure washeld constant. A squeeze ball was attached by a tube to the
cephalad end of the specimen. A 4 mm bore scope (Karl
Storz, Tuttlingen, Germany) was inserted from the outflow
end of the vein specimen. Competent valves under pressure
of 25 mm Hg were closed but a squeeze of the ball
increased pressure on the inflow side and opened the com-
petent valves allowing evaluation of valve motion and cusp
flexibility.
Gross and histologic studies. Four resected vein seg-
ments were preserved in formalin and embedded in meth-
plate a, Distended vein segment with a bicuspid valve
. b, Distended vein segment placed inside the stent valve
the square stent bend (arrow). c, Completed autologous
nstrate valve commissures.ve tem
flow
ip ofylmethacrylate for histologic examinations.
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The results are summarized in the Table. The PAVV
transplant maximal JV diameter ranged from 10.2 mm to
15.4 mm (mean 13.1  1.5 mm). The harvested valves
were successfully attached into four 13mm diameter and to
five 15 mm diameter SVTs. One cusp of one transplanted
vein was accidentally cut during trimming of the excess of
the caudal transplant end. PAVV placements were success-
ful in all nine animals. The mean procedure time, from
harvesting the vein segment to deployment of PAVV to the
opposite JV was 42.6  8.6 min. There was no migration
during or after the PAVVs insertions. Immediate post
placement ascending venograms with contrast medium in-
jection cephalad to the transplanted valve showed unim-
paired blood flow through all PAVVs. Perivalvular leak
between the transplanted valve and the host vein wall was
observed on descending venograms around the outside of
the PAVV in two animals (23%). The size of the SVT was
0.8mm and 1.4mm, respectively, larger than vein diameter
in these two animals. After dilation of the PAVV inflow
part only with a 14 mm angioplasty balloon, the leak
disappeared. Reflux of contrast medium on descending
venogram was present in one valve (12%).
Follow-up venograms at 3 months showed no migra-
tion of the PAVVs. Eight PAVVs (88%) functioned well
with no leak on follow-up venograms prior to sacrifice (Fig 3).
Reflux was observed in the transplanted valve that was cut
during PAVV construction.
Gross examinations of the exposed veins revealed all
PAVVs securely incorporated into the JV wall. The PAVVs
barbs penetrated the vein wall that was seen in all trans-
plants. No reaction or damage to the surrounding struc-
tures was present. There were no signs of stainless steel wire
fracture, corrosion or vein disruption.
Angioscopic examination revealed intact, flexible, non-
thickened valve leaflets in eight specimens (Fig 4, a and b).
The PAVV with one cusp cut exhibited normal function of
one leaflet only. All PAVVs were free of thrombus and
incorporated into the vein wall of the host vessel (Fig 4, c).
Microscopic examination of four PAVVs explanted at 3
months showed thin intact valve leaflets. The findings








1 15.4 15 55
2 12.0 13 43
3 12.8 13 56
4 13.6 15 35
5 10.5 13 30
6 12.8 13 46
7 13.1 15 40
8 14.2 15 37
9 14.4 15 42
Mean 13.1  1.4 42.6  8.6
L, Perivalvular leak; F, good flexibility; R, reflux; C, competent.demonstrated incorporation of the PAVVs into the hostvein wall except for the short edge of the vein wall attached
to the tip of the sinus. Chronic inflammation and foreign
body type giant cells were noted around sutures and wires
where the PAVVs were attached to the venous wall (Fig 5,
a and b).
DISCUSSION
The limitation of the current techniques in the treat-
ment of CDVI prompted exploration of the feasibility of
endovascular transplantation of stent supported autolo-
gous natural valve as a possible treatment alternative.25-27
Dalsing et al explored in canines’ endovascular transplanta-
tion of a JV valve supported with a 6 or 8 mm diameter
Z stent.25 They deployed the valve stent assembly through
a long 16F sheath into the common or external iliac vein. At
1 to 4 weeks follow-up, only one of five valves in an over
dilated recipient vein with a relatively high flow remained
patent; the other four valves were occluded.25 Ofenloch et
al achieved better results in goats with the use of an endo-
scopically harvested JV segments containing a valve sup-
ported by a short 10mmdiameterWallstent.26 After venot-
omy, a 12F sheath was used for placement of the valve stent
device into the opposite JV. At 1 week, all five tested valves
were competent. At 6 weeks, the transplanted vein segment
was fully incorporated into the host vein. Angioscopically,
five of six valves were competent and of normal appearance,
only one valve was obliterated by recanalized thrombus.26
Kucher et al achieved similar good results in canines com-
paring a standard femoral vein interposition with transplan-
tation of a short 8 mm diameter nitinol Symphony stent
supported JV segment and containing a valve into the
femoral vein.27 An 11F sheath was used for placing the
stent device covered from inside and outside by vein wall
into the contra lateral femoral vein. Only one of seven dogs
had bilateral femoral vein occlusions at 2 weeks follow-up.
The remaining six had patent and well functioning valves at
120 days in both the surgical grafts and the transplanted
stent supported JV segments. The surgical grafts exhibited
minimal to moderate stenoses at the suture lines, not seen
with the stented veins.27







0 C F C
0 C F C
0 C F C
L C F C
0 R F R
0 C F C
0 C F C
L C F C
0 C F CP
leakously used by OHSU18-20,28 and others29 due to anatom-
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view demonstrates patency of the transplanted valve (arrows). b, Descending jugular venogram in lateral view
demonstrates competency of the transplanted valve (arrows). c, Ascending venogram in anterior posterior view shows
sinus formation at the stent valve template (arrows).
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femoral vein.30 The time point (3 months) for this study
was chosen based on results with the small intestinal sub-
mucosa covered bioprosthetic venous valve (SIS-BVV).
Initially after implantation up to 1 month, SIS-BVV exhib-
ited its good pliability and function.18,20,21,28 By 3months,
leaflet pliability significantly decreased,18,21 and at 6
months, most of the SIS BVVs became rigid and their
leaflet thickened.18 At 12 months, all SIS BVV were rigid
and nonfunctional.21 This process was caused by neointima
and intimal hyperplasia formation.
We used a homemade frame for attachment of the
Fig 4. Venoscopy of the transplanted valve at 3 mont
leaflets in open position and (b) closed position. c, Spe
bicuspid valve into the host vein.harvested JV segment with valve to SVT for PAVV trans-plantation. Instead of attaching the vein segment with the
valve to commercially available stents,25-27 it was attached
to a SVT that was designed to fit the shape of BV commis-
sure and the valve sinus. The completed PAVV consisted of
a short 15 mm inflow part and BV attached with a few mm
of the vein wall to the middle of the SVT. This attachment
of the BV with only a short border exposed the free valve
border to the endothelial cells of the host vein. After
percutaneous transplantation, the longer bends of the SVT
created sinus in the host vein that allowed proper hemody-
namic condition for the PAVV function (Fig 3, c). This
included good leaflet flexibility and coaptation to assist
Bicuspid valve inside a flow model demonstrates thin
n of the transplanted valve shows incorporation of thehs. a,
cimeblood flow in formation of vortices, which cleared blood
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and all leaflets demonstrated normal cusp pliability at 3
months. Eight PAVVs functioned well with no reflux on
follow-up descending venograms prior to sacrifice. Reflux
was observed in only one PAVV that exhibited normal
function of one leaflet only. The other cusp of this valve was
accidentally cut during the transplantation procedure. All
PAVVs were almost completely incorporated into the vein
wall of the host vessel and were free of thrombus.
Exact sizing, adjusting the transplant valve size to the
SVT diameter is essential for good valve function. To
prevent migration, SVT should be sized approximately 10%
to 15% more in relation to the target vein. The valve
suspension between both shorter square stent bend of the
SVT can be compensated for a few mm in the preparation
process. Using a 10% to 15 % undersized BV allows the
valve’s stretching maximally. Under sizing more than 15%
may lead in PAVV migration in most cases. Oversized
valves of 15% to 20% vein diameter may lead to valve
redundancy and insufficiency.
These results support the reported good patency of
endovenous valve transplants by Ofenloch and Kucher and
show potential of the tested techniques. Long-term 6
months to 1 year studies are necessary before these tech-
niques could be considered for clinical application.
Surgical transplantation of the vein segment with a
native valve into the femoral vein is limited by adverse
anatomical conditions, extensive dissection and developing
stenosis at the anastomotic ends.31 The main advantage of
the PAAV is the ability to transplant venous valve from the
distance to difficult remote locations with failed valves
using percutaneous delivery technique. This method de-
Fig 5. Hematoxylin and eosin stain of transplanted bicuspid valve
at 3 months. a, Longitudinal microscopic view of both trans-
planted leaflets. Arrow points to native valve inside the SVT created
sinus above incompletely incorporated edge of autologous valve
vein wall into the host vein. b, Magnified view (50x).creases prolong transplant ischemia and decreases surgicaltrauma. The mean procedure time, from harvesting the
vein segment to deployment of PAVV to the opposite JV
was 42.6  8.6 minutes. No stenosis was seen in the host
vein at both ends of the transplanted valve similarly as
Kucher et al in their studies.27
CONCLUSION
In conclusion, this study demonstrates that percutane-
ous autogenous valve transplants remain patent and com-
petent without long-term anticoagulation for up to 3
months. The percutaneous autologous venous valve may
provide minimally invasive treatment for patients with
CDVI but long-term studies need to be done to document
its continued patency and function.
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This interesting study by Dr Pavcnik and his group expands
and extends their previous work on the development of an
artificial venous valve. Despite initial promising results, their
most recent data suggest that a different approach may be
needed than a totally artificial venous valve. Building upon
pioneering work by a number of authors, they present an
elegant study in an ovine animal model in which they demon-
strate the feasibility of transplanting a valve from one jugular
vein to another jugular vein percutaneously. This is performed by
attaching the intact vein with its competent valve inside a stent.
They demonstrate at 3months intact, flexible, non-thickened valve
leaflets that were competent by phlebography and angioscopy,
with excellent microscopic analysis. They appropriately point out
the short follow-up of their study and the need for further long-
term data.
This approach, utilizing an autologous vein, is subject to the
same limitation as current valve transplantation procedures, thatpotential advantages include the percutaneous delivery which will
avoid an often difficult recipient vein dissection, especially in the
postthrombotic vein, and the associated risk of perioperative
bleeding in the surgical field with the use of anticoagulation.
Additionally, it has been suggested that transplanted venous valves
may become incompetent as the vein segment dilates, leading
some to wrap their transplanted vein valves with material such as
expanded polytetrafluroethylene, to prevent dilatation. Unfortu-
nately, this may lead to significant perivenous inflammation and
scarring. The stent should act as a barrier to vein dilation and
subsequent valve incompetence.
With the large number of patients affected by chronic venous
insufficiency worldwide, the potential for a solution to the valve
incompetence problem has great clinical potential to supplement
and supplant our current treatment. Although the approach pre-
sented here will require more experimentation and longer follow-
up, the results of the current study provide considerable excite-
ment for this unqiue and timely approach.
